Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ascorbic Acid→

Ascorbic Acid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
50-81-7
Molecular formula
C6H8O6
Molecular weight
176.12 g/mol
Drug class
Vitamin C (ascorbic acid)water-soluble vitamin and reducing agent
Mechanism of action
Acts as an electron donor and cofactor for several dioxygenases, including prolyl and lysyl hydroxylases required for collagen synthesis, and enzymes involved in carnitine and catecholamine biosynthesis. It also functions as an antioxidant and supports normal immune function.
Indications / reported uses
  • Prevention and treatment of vitamin C deficiency and scurvy
  • Supplementation when dietary intake or absorption is inadequate; use for other conditions should not be inferred from nutritional or biochemical effects alone

Sources: NIH Office of Dietary Supplements — Vitamin C fact sheet · NHS — Vitamin C · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ascorbic Acid Environmental Risk Assessment (ERA) (the Ascorbic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.